申请人:Takeda Pharmaceutical Company Limited
公开号:EP2336107A2
公开(公告)日:2011-06-22
A compound represented by the formula (II-a)
wherein
X1 is -SO2-, -SO2-N (R7) - (wherein R7 is a hydrogen atom or an optionally substituted hydrocarbon group), -N(R8)-SO2- (wherein R8 is a hydrogen atom or an optionally substituted hydrocarbon group), -N(R9)- (wherein R9 is a hydrogen atom or an optionally substituted hydrocarbon group) or -O-,
Y1 is a C1-8 alkylene group optionally having 1 to 3 substituents selected from a halogen atom and hydroxy, R10 is an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group,
R11 is (i) a hydrogen atom, (ii) an optionally substituted hydrocarbon group, (iii) a 2- or 3-thienyl group optionally substituted by 1 to 3 substituents, (iv) a 2- or 3-benzo[b]thienyl group optionally substituted by 1 to 5 substituents (v) a 2- or 3-furyl group optionally substituted by 1 to 3 substituents, (vi) a 2-, 3- or 4-pyridyl group optionally substituted by 1 to 3 substituents, (vii) a 3- or 4-pyrazolyl group optionally substituted by 1 to 3 substituents, (viii) a 2-, 4- or 5-pyrimidinyl group optionally substituted by 1 to 3 substituents, R12 and R13 are each independently a hydrogen atom, an optionally substituted hydrocarbon group, an acyl group, a halogen atom, a cyano group or a nitro group (provided that R12 and R13 are not simultaneously hydrogen atoms), and R14 and R15 are each independently a hydrogen atom or an optionally substituted hydrocarbon group, or a salt thereof.
由式(II-a)代表的化合物
其中
X1 是-SO2-、-SO2-N (R7)-(其中 R7 是氢原子或任选取代的烃基)、-N(R8)-SO2-(其中 R8 是氢原子或任选取代的烃基)、-N(R9)-(其中 R9 是氢原子或任选取代的烃基)或-O-、
Y1 是 C1-8 烷基,可选具有 1 至 3 个选自卤原子和羟基的取代基,R10 是任选取代的烃基或任选取代的杂环基、
R11是(i)氢原子,(ii)任选取代的烃基,(iii)任选被 1 至 3 个取代基取代的 2-或 3-噻吩基,(iv)任选被 1 至 5 个取代基取代的 2-或 3-苯并[b]噻吩基,(v)任选被 1 至 3 个取代基取代的 2-或 3-呋喃基,(vi)任选被 1 至 3 个取代基取代的 2-、3-或 4-吡啶基,(vii)任选被 1 至 3 个取代基取代的 3-或 4-吡唑基、(viii) 被 1 至 3 个取代基任选取代的 2-、4-或 5-嘧啶基,R12 和 R13 各自独立地为氢原子、任选取代的烃基、酰基、卤素原子、氰基或硝基(但 R12 和 R13 不能同时为氢原子),R14 和 R15 各自独立地为氢原子或任选取代的烃基或其盐。